ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1461

Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population

Boulos Haraoui1, Algis V Jovaisas2, William G. Bensen3, Rafat Y. Faraawi4, John T. Kelsall5, Sanjay Dixit6, Emmanouil Rampakakis7, John S. Sampalis7, Francois Nantel8, Susan M. Otawa9, Allen J. Lehman9 and May Shawi10, 1Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 5Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 6McMaster University, Hamilton, ON, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Infection, remission, rheumatoid arthritis (RA) and steroids

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients treated with a traditional or biologic DMARD based on the patient’s clinical status. The objective is to examine the effect of chronic systemic CS treatment at different doses on the incidence of infections in RA patients treated with IFX in a real-life setting. The impact of CS use on the sustainability of remission was also assessed.

Methods:

BioTRAC is an ongoing, Canadian, prospective, registry of rheumatology patients initiating treatment with IFX or golimumab as first biologics or after having been treated with a biologic for less than 6 mos. RA patients treated with IFX who were enrolled between 2002 and 2012 were included. Cox regression was used to examine the time-dependent association between systemic CS dose (no CS, ≤5 mg, >5 mg) and the incidence of first infection, while adjusting for possible confounders, and to assess the sustainability of remission.

Results:

838 RA patients were included in the analyses. Mean (SD) age of the patient cohort was 56.6 (13.5) yrs and mean (SD) duration since diagnosis was 10.5 (9.8) yrs. At initiation of treatment, 38.2% of patients were treated with a systemic CS. After a mean (SE) follow-up of 51.3 (1.7) mos, 310 infections were reported for 19.7% of patients (19.6 /100 PYs). Among these, the majority (90.0%) were non-serious infections. Multivariate survival analysis using Cox regression showed that, upon adjusting for enrolment period, age, disease duration, number of steroid administrations, and HAQ-DI, the hazard ratio (HR) (95%CI) for acquiring an infection was 2.48 (1.24-4.98) in patients treated with high dose (>5 mg) CS compared to patients not receiving CS. Treatment with low dose CS was also associated with an increased hazard for infection (HR (95%CI) = 2.12 (0.97-4.66)) which did not reach statistical significance. Consistent with previous studies, increased HAQ-DI (HR (95%CI) = 1.51 (1.15-1.92)) and disease duration (HR (95%CI) = 1.01 (1.00-1.03)) were also identified as significant predictors. CS use was continued in 15% of cases despite the achievement of remission (DAS28-CRP: 15.2%; CDAI: 15.7%). Survival analysis did not show a significant positive effect of steroid use on sustainability of remission [HRDAS28-CRP (95%CI) = 1.40 (0.95-2.06); HRCDAI (95%CI) = 1.19(0.75-1.88)]

Conclusion:

Treatment with systemic CS was associated with an increased hazard ratio for acquiring an infection upon adjusting for possible confounders. Despite the achievement of remission, steroid use was continued in 15% of cases without having an impact on sustainability of remission. We show that treatment with systemic CS is an independent predictor of infection in patients treated with anti-TNF agents and suggest that the use of concomitant medications should be considered in the interpretation of safety data.

References: 1. J Rheumatol 2012;39;1559-1582


Disclosure:

B. Haraoui,
None;

A. V. Jovaisas,
None;

W. G. Bensen,
None;

R. Y. Faraawi,
None;

J. T. Kelsall,
None;

S. Dixit,
None;

E. Rampakakis,
None;

J. S. Sampalis,
None;

F. Nantel,
None;

S. M. Otawa,

Janssen Canada,

3;

A. J. Lehman,

Janssen Canada,

3;

M. Shawi,

Janssen Canada,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/corticosteroid-use-in-rheumatoid-arthritis-patients-on-infliximab-treatment-implications-based-on-a-real-world-canadian-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology